Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 94 filers reported holding Y-MABS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $84,922 | -19.7% | 15,582 | 0.0% | 0.00% | – |
Q2 2023 | $105,802 | +31.1% | 15,582 | -3.3% | 0.00% | – |
Q1 2023 | $80,731 | +2.7% | 16,114 | 0.0% | 0.00% | – |
Q4 2022 | $78,636 | -63.0% | 16,114 | +9.3% | 0.00% | – |
Q3 2022 | $212,594 | -6.8% | 14,743 | -2.2% | 0.00% | – |
Q2 2022 | $228,085 | +25.4% | 15,075 | -1.6% | 0.00% | – |
Q1 2022 | $181,942 | -41.7% | 15,315 | -20.3% | 0.00% | – |
Q4 2021 | $312,000 | -42.0% | 19,220 | +1.9% | 0.00% | – |
Q3 2021 | $538,000 | -21.2% | 18,856 | -6.6% | 0.00% | -100.0% |
Q2 2021 | $683,000 | +27.0% | 20,197 | +13.6% | 0.00% | – |
Q1 2021 | $538,000 | -41.5% | 17,785 | -4.2% | 0.00% | -100.0% |
Q4 2020 | $920,000 | +34.3% | 18,573 | +4.1% | 0.00% | 0.0% |
Q3 2020 | $685,000 | -17.3% | 17,840 | -1.6% | 0.00% | 0.0% |
Q2 2020 | $828,000 | +106.5% | 18,127 | +18.1% | 0.00% | – |
Q1 2020 | $401,000 | -0.2% | 15,353 | +19.3% | 0.00% | – |
Q4 2019 | $402,000 | +15.9% | 12,868 | -4.4% | 0.00% | – |
Q3 2019 | $347,000 | +16.1% | 13,467 | +2.9% | 0.00% | – |
Q2 2019 | $299,000 | – | 13,089 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 191,176 | $932,939 | 3.08% |
Sofinnova Investments, Inc. | 2,194,278 | $10,708,077 | 0.64% |
Artal Group S.A. | 400,000 | $1,952 | 0.11% |
Polar Capital Holdings Plc | 1,991,929 | $9,720,614 | 0.08% |
ASHFORD CAPITAL MANAGEMENT INC | 98,870 | $482,486 | 0.08% |
Soleus Capital Management, L.P. | 87,182 | $425,448 | 0.06% |
GSA CAPITAL PARTNERS LLP | 99,160 | $484 | 0.06% |
Cormorant Asset Management, LP | 150,000 | $732 | 0.05% |
CORNERCAP INVESTMENT COUNSEL INC | 48,233 | $235,377 | 0.04% |
XTX Topco Ltd | 38,574 | $188,241 | 0.04% |